This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Liver cancer	Core 1 synthase glycoprotein-N- acetylgalactosamine 3- β -galactosyltransferase 1 (C1GALT1)	Human tissue and mouse studies suggest inhibiting C1GALT1 could help treat hepatocellular carcinoma (HCC). In patient samples, C1GALT1 was higher in HCC tissues than in adjacent normal tissues. In HCC patients, high C1GALT expression in tumor tissue was associated with more advanced tumor stage, increased metastasis and decreased survival compared with low C1GALT expression. In a mouse xenograft model of human HCC, small hairpin RNA-mediated knockdown of <i>C1GALT1</i> decreased tumor growth compared with control shRNA. Next steps could include developing and evaluating pharmacological inhibitors of C1GALT1.	Patent and licensing status unavailable	Wu, Y.-M. <i>et al. Cancer Res.</i> ; published online July 5, 2013; doi:10.1158/0008-5472.CAN-13-0869 Contact: Min-Chuan Huang, National Taiwan University College of Medicine, Taipei, Taiwan e-mail: mchuang@ntu.edu.tw
<i>SciBX</i> 6(31); doi:10.1038/scibx.2013.822 Published online Aug. 15, 2013				